Skip to main content
Equibles
DSGN logo

DSGN · Design Therapeutics, Inc. · Documents

Track DSGN — free

Use DSGN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research DSGN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$10.52 +0.31 (+3.04%) Play latest call Q3 2025 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$653.81M
Shares
64.04M
Volume · Nov 9 70.68K Avg daily vol (3M) 581.33K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $0 10-K filed Mar 9, 2026 Quarterly report New FY2026 Q3 Net loss $20.29M 10-Q filed Nov 4, 2026 Latest results New DT-216P2 registrational update and RESTORE-FA data milestones ahead 8-K filed Nov 4, 2026 Earnings call Q3 2025 earnings call Held Nov 5, 2025
2026
Nov 4
Registration statement S-3
$300,000,000 shelf offering proposed

Design Therapeutics, Inc. proposes to offer up to $300,000,000 of common stock, preferred stock, debt securities and warrants in one or more offerings; sales cannot occur until the registration statement becomes effective.

Read from the first part of this long document
3 source passages
Design Therapeutics, Inc. From time to time, we may offer and sell up to $300,000,000 of any combination of shares of our common stock, shares of our preferred stock, debt securities and warrants to purchase any of such securities, in one or more offerings as described in this prospectus. We may not sell these securities until the U.S. Securities and Exchange Commission declares our registration statement effective. Open the document at this passage
Nov 4
Current report 8-K
DT-216P2 registrational update and RESTORE-FA data milestones ahead

Design Therapeutics expects a DT-216P2 registrational-plan update in Q4 2026 and 12-week RESTORE-FA data in Q1 2027; third-quarter net loss was $20.3 million, with $208.6 million in cash and securities.

Financial results
3 source passages
DT-216P2 Anticipated Milestones: Registrational Plan Update in Q4 2026 and 12-Week RESTORE-FA Data in Q1 2027 Net Loss: Net loss was $20.3 million for the quarter ended September 30, 2026. Cash Position: Cash, cash equivalents and investment securities were $208.6 million as of September 30, 2026. Open the document at this passage
May 18
Current report 8-K
Other events AI summary on its way
Apr 28
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $0 Net loss $17.64M Diluted EPS -$0.29
Mar 9
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $0 Net loss $69.79M Diluted EPS -$1.22
2025
Mar 10
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $0 Net loss $49.59M Diluted EPS -$0.88
2024
2023
Showing 1–50 of 87 documents
Key facts CIK 1807120 CUSIP 25056L103 13F (30d) 53 filings 41 filers Visit website Investor relations